Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chloroquine phosphate plus standard therapy versus placebo plus standard therapy in mild/common COVID-19
ChiCTR2000030031Phase 4Suspended
- Sponsor
- The Sixth Affiliated Hospital of Guangzhou Medical University (Qingyuan People's Hospital)
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia comparing Chloroquine phosphate group with Placebo group (2 arms). Primary endpoint: Time of conversion to negative of novel coronavirus nucleic acid. Started Feb 2020; status: suspended.
02
Drugs
chloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on ChiCTR2000030031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030031.